SEARCH

SEARCH BY CITATION

References

  • 1
    El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
  • 2
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
  • 3
    Nahon P, Zucman-Rossi J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol 2012;57:663-674.
  • 4
    Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
  • 5
    Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-1894.
  • 6
    Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010;42:21-23.
  • 7
    Seth D, Daly AK, Haber PS, Day CP. Patatin-like phospholipase domain containing 3: a case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. Hepatology 2010;51:1463-1465.
  • 8
    Stickel F, Buch S, Lau K, zu Schwabedissen HM, Berg T, Ridinger M, et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011;53:86-95.
  • 9
    Trépo E, Gustot T, Degre D, Lemmers A, Verset L, Demetter P, et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011;55:906-912.
  • 10
    Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011;54:60-69.
  • 11
    Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, et al. Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011;53:791-799.
  • 12
    Corradini SG, Burza MA, Molinaro A, Romeo S. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology 2011;53:1776; author reply, 1777.
  • 13
    Hamza S, Petit JM, Masson D, Jooste V, Binquet C, Sgro C, et al. PNPLA3 rs738409 GG homozygote status is associated with increased risk of hepatocellular carcinoma in cirrhotic patients. J Hepatol 2012;56:S281-S282.
  • 14
    Nischalke HD, Berger C, Luda C, Berg T, Müller T, Grünhage F, et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PloS One 2011;6:e27087.
  • 15
    Falleti E, Fabris C, Cmet S, Cussigh A, Bitetto D, Fontanini E, et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011;31:1137-1143.
  • 16
    Trépo E, Guyot E, Ganne-Carrie N, Degre D, Gustot T, Franchimont D, et al. PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 2012;55:1307-1308.
  • 17
    Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol 2013;58:312-318.
  • 18
    Burza MA, Pirazzi C, Maglio C, Sjoholm K, Mancina RM, Svensson PA, et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis 2012;44:1037-1041.
  • 19
    Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008;37:120-132.
  • 20
    Ioannidis JP, Rosenberg PS, Goedert JJ, O'Brien TR; International Meta-analysis of HIVHG. Commentary: meta-analysis of individual participants' data in genetic epidemiology. Am J Epidemiol 2002;156:204-210.
  • 21
    Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010;340:c221.
  • 22
    Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials 1985;6:271-279.
  • 23
    Takeuchi Y, Ikeda F, Moritou Y, Hagihara H, Yasunaka T, Kuwaki K, et al. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol 2013;48:405-412.
  • 24
    Valenti L, Motta B, Soardo G, Bertelli C, Sangiovanni A, Rametta R, et al. I148M PNPLA3 polymorphism is associated with clinical features in patients with hepatocellular carcinoma. J Hepatol 2012;56:S129.
  • 25
    Fornasiere E, Cmet S, Cussigh A, Bitetto D, Furnolo E, Bignulin S, et al. PNPLA3 rs738409 C/G polymorphism in liver cirrhosis: relationship with the etiology of liver disease and HCC occurence. J Hepatol 2011;54:S244-S245.
  • 26
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
  • 27
    Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 2005;34:1319-1328.
  • 28
    McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, ed. Frontiers in Econometrics. New York: Academic; 1973:105-142.
  • 29
    Akaike H. Fitting autoregressive models for prediction. Ann Inst Stat Math 1969;21:243-247.
  • 30
    Borenstein M. Introduction to Meta-Analysis. Chichester, UK: John Wiley & Sons; 2009:xxviii.
  • 31
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
  • 32
    Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol 2008;37:136-146.
  • 33
    Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med 2005;24:1291-1306.
  • 34
    Deeks JJ, Altman DG, Bradburn MJ: Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care—Meta-Analysis in Context. London: BMJ Books; 2005:285-312.
  • 35
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
  • 36
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
  • 37
    Little J, Higgins JPT (eds). The HuGENet™ HuGE Review Handbook, version 1.0. Atlanta, GA; Centers for Disease Control and Prevention; 2006.
  • 38
    Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000;53:207-216.
  • 39
    Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin M, Stahlman M, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 2012;57:1276-1282.
  • 40
    Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-1217.
  • 41
    Pare G, Ridker PM, Rose L, Barbalic M, Dupuis J, Dehghan A, et al. Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci. PLoS Genet 2011;7:e1001374.
  • 42
    Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, et al. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol 2012;12:111.
  • 43
    Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957-969.
  • 44
    Alisi A, Ghidinelli M, Zerbini A, Missale G, Balsano C. Hepatitis C virus and alcohol: same mitotic targets but different signaling pathways. J Hepatol 2011;54:956-963.